AlphAIalphai — Financial news for AI agents
MarketBeatDEC 233 min read$OMCL

Omnicell, Inc. $OMCL Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC significantly reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 83.3% in Q2, selling over 134,000 shares. Despite this, other institutions like Invesco and Wellington increased their holdings, with institutional investors now owning 97.70% of the company. Omnicell, a healthcare technology firm specializing in medication management, maintains a "Hold" consensus rating with a $43 target price, though one analyst upgraded its target to $50 with a "Buy" rating.

Original reporting
MarketBeat · MarketBeat
Published Dec 23, 2025, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Dec 23, 2025, 11:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Omnicell, Inc. $OMCL Shares Sold by Squarepoint Ops LLC — source image
Source · MarketBeat
Decision brief

The 30-second read

$OMCLNeutralMed
01

Why it matters

While insider selling often raises caution, the overall institutional support and analyst outlook suggest limited immediate downside. Technical analysis and upcoming catalysts should be considered for a comprehensive view.

02

Market read

The news has moderate relevance for traders focusing on healthcare tech stocks, with some caution advised due to insider activity.

03

What to watch

Potential upcoming catalysts, such as product launches or earnings reports, could offset negative signals.

Timing: Moderate; news is recent but not urgent for immediate trading decisions.

Background

Omnicell is a healthcare technology firm specializing in medication management solutions. Recent insider activity shows significant share sale by Squarepoint Ops LLC, which could reflect strategic repositioning or concerns.

Company-level read

Ticker impact

$OMCLNeutralMedium confidence
Context

High relevance due to significant insider activity and institutional ownership changes.

Expected impact

Minimal short-term price movement; potential slight decline or sideways trend.

Evidence & confidence

The substantial insider sale could be perceived as a negative signal, but the overall institutional support and analyst ratings suggest limited downside. Technical levels and current valuation should be monitored for confirmation.

Market effects

Sector

Limited; the healthcare technology sector remains stable with no immediate sector-wide impact.

Regional

Negligible; no regional market effects expected from this news.

Global

Low; company-specific news with minimal global market influence.

Counterpoint

What could challenge this read

The insider sale might indicate upcoming challenges or overvaluation; consider reducing exposure.

Key entities

  • Company
    Omnicell, Inc.

    Healthcare technology company focusing on medication management solutions.

  • Institutional Investor
    Squarepoint Ops LLC

    Hedge fund that sold a significant portion of its holdings.

  • Institutional Investor
    Invesco

    Increased holdings in Omnicell, indicating continued institutional confidence.

  • Institutional Investor
    Wellington

    Increased holdings, supporting stability.

Read at source← All news

Related articles

JUL 30
$OMCLMedAI 8/10

Omnicell (OMCL) Stock Trades Down, Here Is Why

Omnicell (NASDAQ: OMCL) shares fell 9.9% after the company reported Q2 results that beat expectations but issued weaker guidance. Omnicell posted Q2 revenue of $312.2 million and adjusted EPS of $0.94. For Q3, it projected revenue of about $304 million, below estimates, and next-quarter EPS guidance missed consensus.

financialcontent.com4 min
JUL 30
$OMCLHigh

OMNICELL, INC. (OMCL): Results of Operations and Financial Condition

OMNICELL, INC. (OMCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q2-26.htm EX-99.1 Document Exhibit 99.1 Contact: Omnicell, Inc. David Unger 4220 North Freeway Vice President, Investor Relations Fort Worth, TX 76137 ir@omnicell.com Omnicell Announces Second Quarter 2026 Financial Results Omnicell delivers solid second quart

SEC EDGAR 8-K6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min
AUG 9
$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

globes.co.il4 min